Related Experiment Videos
Identification of a novel truncated alphaIIb integrin
1Department of Radiation Oncology, Wayne State University, and Barbara Ann Karmanos Cancer Center, Detroit, Michigan 48202, USA.
Cancer Research
|November 11, 1998
Summary
A novel truncated integrin alphaIIb variant, lacking cytoplasmic tails, is secreted by tumor cells. This finding reveals a new mechanism for integrin involvement in cancer progression and extracellular matrix interactions.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Integrin alphaIIb beta3 is crucial for tumor cell adhesion, spreading, and migration.
- The cytoplasmic tails of integrins are known to mediate these cellular functions.
Purpose of the Study:
- To investigate the integrin alphaIIb (ITGA2B) gene expression in human tumor cells.
- To identify and characterize novel variants of integrin alphaIIb.
Main Methods:
- 3' rapid amplification of cDNA ends (RACE) was used to amplify alphaIIb cDNAs.
- Expression analysis was performed in leukemia, prostate adenocarcinoma, melanoma cells, platelets, and normal epithelial cells.
Main Results:
- Two alphaIIb cDNAs were identified: wild-type and a novel truncated variant.
- The truncated alphaIIb variant lacks transmembrane and cytoplasmic domains.
- This variant is expressed in tumor cells (leukemia, prostate, melanoma) but not in platelets or normal epithelial cells.
- Tumor cells secrete the truncated alphaIIb and deposit it in the extracellular matrix.
Conclusions:
- This study reports the first naturally occurring variant of an alpha integrin lacking transmembrane and cytoplasmic tails.
- The secreted truncated alphaIIb may play a role in tumor cell behavior and extracellular matrix remodeling.
- This discovery opens new avenues for understanding integrin function in cancer.